Literature DB >> 9621199

Emergence of the M phenotype of erythromycin-resistant pneumococci in South Africa.

C A Widdowson1, K P Klugman.   

Abstract

Erythromycin-resistant pneumococci have been isolated in South Africa since 1978; however, from 1987 to 1996, resistance to macrolides was only detected in 270 (2.7%) of 9,868 blood or cerebrospinal fluid (CSF) pneumococcal isolates, most of which were obtained from the public sector. In South Africa, macrolide use in the public sector is estimated at 56% of that in the private sector. Most erythromycin-resistant strains (89%) exhibited resistance to erythromycin and clindamycin (macrolide-lincosamide-streptogramin B phenotype). In the United States, most erythromycin-resistant pneumococci exhibit the newly described M phenotype (resistance to erythromycin alone), associated with the mefE gene. The M phenotype in South Africa increased significantly in the last 10 years, from 1 of 5,115 to 28 of 4,735 of blood and CSF isolates received from 1987 to 1991 compared with 1992 to 1996 (p = 5 x 10(-7)). These data suggest that, although macrolide resistance in pneumococci remains low in the public sector, the mefE gene is rapidly emerging in South Africa.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9621199      PMCID: PMC2640124          DOI: 10.3201/eid0402.980216

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


DNA was extracted from pneumococcal isolates by using a lysis solution consisting of 0.1% sodium deoxycholate as described in (11), except that we used plate rather than broth cultures. Seventy-eight MLS strains were probed for the ermAM gene by using dot blots. The probe (supplied by P. Courvalin, Pasteur Institute, Paris, France) (Escherichia coli JM83/pUC19 560bp Ssp1 intragenic fragment of ermB) was labeled with digoxygenin by using random primed labeling (DIG DNA Labeling and Detection Kit; Boeringer, Mannheim, Germany). Hybridization and detection were performed following manufacturer's instructions (DIG DNA Labeling and Detection Kit; Boeringer, Mannheim, Germany). PCR was also used to detect ermAM in 30 strains according to standard conditions, with an annealing temperature of 58°C. We used the following primers: forward primer, 5'-CGAGTGAAAAAGTACTCAACC, reverse primer, 5'-GGCGTGTTTCATTGCTTGATG). Published primers for the mefE gene (5'-AGTATCATTAATCACTAGTGC, and 5'-TTCTTCTGGTACTAAAAGTGG) were used to detect mefE through PCR amplification in 13 M strains. Amplification was performed in a Perkin Elmer Cetus DNA Thermal Cycler under standard reaction conditions, with an annealing temperature of 56oC.
  26 in total

1.  Antipneumococcal activities of RP 59500 (quinupristin-dalfopristin), penicillin G, erythromycin, and sparfloxacin determined by MIC and rapid time-kill methodologies.

Authors:  G A Pankuch; C Lichtenberger; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

2.  Susceptibility of penicillin-susceptible and -resistant pneumococci to dirithromycin compared with susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin.

Authors:  M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

3.  The continued emergence of drug-resistant Streptococcus pneumoniae in the United States: an update from the Centers for Disease Control and Prevention's Pneumococcal Sentinel Surveillance System.

Authors:  J C Butler; J Hofmann; M S Cetron; J A Elliott; R R Facklam; R F Breiman
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

4.  Substrate- and antibiotic-binding sites at the peptidyl-transferase centre of Escherichia coli ribosomes. Studies on the chloramphenicol. lincomycin and erythromycin sites.

Authors:  R Fernandez-Munoz; R E Monro; R Torres-Pinedo; D Vazquez
Journal:  Eur J Biochem       Date:  1971-11-11

5.  Detection of erythromycin-resistant determinants by PCR.

Authors:  J Sutcliffe; T Grebe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

6.  Clinical and nasopharyngeal isolates of unusual multiply resistant pneumococci.

Authors:  K P Klugman; H J Koornhof; V Kuhnle
Journal:  Am J Dis Child       Date:  1986-11

7.  In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

8.  Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system.

Authors:  J Sutcliffe; A Tait-Kamradt; L Wondrack
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

9.  Resistance patterns in Turkey.

Authors:  D Gür; S Unal; H E Akalin
Journal:  Int J Antimicrob Agents       Date:  1995-09       Impact factor: 5.283

10.  Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life.

Authors:  B M Gray; G M Converse; H C Dillon
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

View more
  12 in total

Review 1.  Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants.

Authors:  M C Roberts; J Sutcliffe; P Courvalin; L B Jensen; J Rood; H Seppala
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

2.  Mechanisms of macrolide resistance in clinical pneumococcal isolates in France.

Authors:  F Fitoussi; C Doit; P Geslin; N Brahimi; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Serotype 19f multiresistant pneumococcal clone harboring two erythromycin resistance determinants (erm(B) and mef(A)) in South Africa.

Authors:  L McGee; K P Klugman; A Wasas; T Capper; A Brink
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

4.  Prevalence and mechanisms of macrolide resistance in clinical isolates of group A streptococci from Ontario, Canada.

Authors:  J C De Azavedo; R H Yeung; D J Bast; C L Duncan; S B Borgia; D E Low
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

Review 5.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 6.  Molecular detection of the macrolide efflux gene: to discriminate or not to discriminate between mef(A) and mef(E).

Authors:  Corné H W Klaassen; Johan W Mouton
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

7.  Patterns of macrolide resistance determinants among community-acquired Streptococcus pneumoniae isolates over a 5-year period of decreased macrolide susceptibility rates.

Authors:  P Oster; A Zanchi; S Cresti; M Lattanzi; F Montagnani; C Cellesi; G M Rossolini
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

8.  Serotypes and genotypes of invasive Streptococcus pneumoniae before and after PCV10 implementation in southern Brazil.

Authors:  Juliana Caierão; Paulina Hawkins; Fernando Hayashi Sant'anna; Gabriela Rosa da Cunha; Pedro Alves d'Azevedo; Lesley McGee; Cícero Dias
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

9.  Molecular epidemiology of penicillin-susceptible non-beta-lactam-resistant Streptococcus pneumoniae isolates from Greek children.

Authors:  D Bogaert; P W M Hermans; I N Grivea; G S Katopodis; T J Mitchell; M Sluijter; R De Groot; N G Beratis; G A Syrogiannopoulos
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

Review 10.  Resistance to macrolide, lincosamide, streptogramin, ketolide, and oxazolidinone antibiotics.

Authors:  Marilyn C Roberts
Journal:  Mol Biotechnol       Date:  2004-09       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.